Welcome to International Journal of Genetic Medicine and Gene Therapy

Dr. Shicheng Guo

Affiliation :
University of Wisconsin-Madison, Wisconsin, USA,United States

Biography :

Dr. Shicheng Guo is an Assistant Scientist at the University of Wisconsin-Madison. He received his Ph.D. degree at Fudan University (Shanghai, China) in 2015 and completed three postdoctoral training positions at the School of Public Health (UThealth), University of Texas and the Department of Bioengineering, University of California, San Diego (UCSD) and Marshfield Clinic Research Institute (MCRI). Dr. Guo started his Postdoctoral Fellow position in MCRI in February 2020 and works on genetic and epigenetic research studying human diseases in Dr. Steven Schrodi's lab with a focus on autoimmune diseases and cancers. He received the Computation and Informatics in Biology and Medicine (CIBM) training program Postdoctoral Fellowship in 2019 at UW-Madison. In the past several years, as the first and co-first author, Dr. Guo published his works in Nature Genetics, Blood, Journal of Medical Genetics, and Clinical Epigenetics. Dr. Guo’s research interest in UW-Madison concentrates on genetics and epigenetics interaction to advance precision medicine and novel drug-targets discovery and development. This work includes identifying epigenetic biomarkers and drug targets for cancer and auto-immune diseases, novel genetic susceptibility and pharmacogenomics (PGx) and pharmaco-epigenomics (PeGx) genes for rheumatoid arthritis (RA), systemic sclerosis (SSc) and ankylosing spondylitis (AS) and related drug response, resistance and persistence. 

Research Interest :

1. Interaction between Genetics and Epigenetics in Precision Medicine.
2. Epigenetic biomarker for cancer and autoimmnue diseases.
3. Novel Genetic Suscepitibility Genes for Rheumatoid Arthritis, Systemic Sclerosis, Ankylosing Spondylitis.
4. Pharmacogenomics for Rheumatoid Arthritis, Systemic Sclerosis, Ankylosing Spondylitis.
5. Drug Response, Resistance and Persistence based on pharmaco-genomics (PGx) and pharmaco-epigenomics (PeGx)
6. Deep learning in cancer and autoimmnue diseases diagnsotic and prognostic prediction and machanism discovery.